Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

No AccessJournal of UrologyAdult Urology1 Sep 2021Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic HyperplasiaThis article is commented on by the following:Editorial CommentEditorial Comment Kevin T. McVary, Marc C. Gittelman, Kenneth A. Goldberg, Kalpesh Patel, Neal D. Shore, Richard M. Levin, Marc Pliskin, J. Randolf Beahrs, David Prall, Jed Kaminetsky, Barrett E. Cowan, Christopher H. Cantrill, Lance A. Mynderse, James C. Ulchaker, Nicholas N. Tadros, Steven N. Gange, and Claus G. Roehrborn Kevin T. McVaryKevin T. McVary *Correspondence: Center for Male Health, Stritch School of Medicine, Loyola University Medical Center, 2160 S. First Ave., Maywood, Illinois 60153 telephone: 708-216-3166; FAX: 708-216-6585; E-mail Address: [email protected] Loyola University Medical Center, Maywood, Illinois Financial interest and/or other relationship with Boston Scientific, NIDDK, Astellas, Olympus, SRS Medical Systems, Medeonbio, Uronext LL. Patent holder: SMA penile prosthesis (US20130131443), magnetic induction SMA (US506777291). More articles by this author , Marc C. GittelmanMarc C. Gittelman South Florida Medical Research, Aventura, Florida Financial interest and/or other relationship with NxThera. More articles by this author , Kenneth A. GoldbergKenneth A. Goldberg University of Texas Southwestern, Lewisville, Texas More articles by this author , Kalpesh PatelKalpesh Patel Arizona Institute of Urology, Tucson, Arizona More articles by this author , Neal D. ShoreNeal D. Shore Carolina Urologic Research Center, Myrtle Beach, South Carolina Financial interest and/or other relationship with NxThera. Financial interest and/or other relationship with Boston Scientific, TELEFLEX, Zenflow, Medeon, GSK. More articles by this author , Richard M. LevinRichard M. Levin Chesapeake Urology Research Associates, Towson, Maryland Financial interest and/or other relationship with Boston Scientific, TELEFLEX, Zenflow, Medeon, GSK. More articles by this author , Marc PliskinMarc Pliskin The Urology Group, Cincinnati, Ohio More articles by this author , J. Randolf BeahrsJ. Randolf Beahrs Minnesota Urology, Woodbury, Minnesota More articles by this author , David PrallDavid Prall Minnesota Urology, Woodbury, Minnesota More articles by this author , Jed KaminetskyJed Kaminetsky Manhattan Medical Research, New York, New York More articles by this author , Barrett E. CowanBarrett E. Cowan Urology Associates of Denver, Englewood, Colorado Financial interest and/or other relationship with Procept Biorobotics. More articles by this author , Christopher H. CantrillChristopher H. Cantrill Urology San Antonio Research, San Antonio, Texas Financial interest and/or other relationship with Boston Scientific, TELEFLEX, Zenflow, Medeon, GSK. More articles by this author , Lance A. MynderseLance A. Mynderse Mayo Clinic, Rochester, Minnesota More articles by this author , James C. UlchakerJames C. Ulchaker Cleveland Clinic, Cleveland, Ohio Financial interest and/or other relationship with Boston Scientific, TELEFLEX, Zenflow, Medeon, GSK. More articles by this author , Nicholas N. TadrosNicholas N. Tadros Southern Illinois University, Springfield, Illinois Financial interest and/or other relationship with NxThera. Financial interest and/or other relationship with Boston Scientific, TELEFLEX, Zenflow, Medeon, GSK. More articles by this author , Steven N. GangeSteven N. Gange Western Urologic Clinic, Salt Lake City, Utah Financial interest and/or other relationship with NeoTract. More articles by this author , and Claus G. RoehrbornClaus G. Roehrborn University of Texas Southwestern, Dallas, Texas Financial interest and/or other relationship with Boston Scientific, TELEFLEX, Zenflow, Medeon, GSK. More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001778AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We present final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor therapy (Rezūm™) for treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia. Materials and Methods: A total of 197 subjects >50 years of age with International Prostate Symptom Score ≥13, maximum flow rate ≤15 ml/second and prostate volume 30 to 80 cc were randomized and followed for 5 years. From the control arm of 61 subjects, a subset of 53 subjects requalified and after 3 months received treatment as part of the crossover group and were also followed for 5 years. The total number of vapor treatments to each lobe of the prostate was determined by length of prostatic urethra and included middle lobe treatment per physician discretion. Results: Significant improvement of lower urinary tract symptoms was observed at <3 months post-thermal therapy, remaining durable through 5 years in the treatment group (International Prostate Symptom Score reduced 48%, quality of life increased 45%, maximum flow rate improved 44%, Benign Prostatic Hyperplasia Impact Index decreased 48%). Surgical re-treatment rate was 4.4% with no reports of device or procedure related sexual dysfunction or sustained de novo erectile dysfunction. Results within the crossover group were similar through 5 years. Conclusions: Minimally invasive treatment with water vapor thermal therapy provides significant and durable symptom relief as well as flow rate improvements through 5 years, with low surgical re-treatment rates and without impacting sexual function. It is a versatile therapy, providing successful treatment to obstructive lateral and middle lobes. References 1. : The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am 2016; 43: 289. Google Scholar 2. : Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline amendment 2019. J Urol 2019; 202: 592. Link, Google Scholar 3. : BPH: why do patients fail medical therapy?Curr Urol Rep 2019; 20: 40. Google Scholar 4. : EAU guidelines on management of non-neurogenic male LUTS. Presented at 2020 EAU Annual Congress, Amsterdam, Arnhem, The Netherlands. Available at http://uroweb.org/guidelines/compilations-of-all-guidelines/. Google Scholar 5. : The adjustable transobturator male system in stress urinary incontinence after transurethral resection of the prostate. Urology 2017; 109: 184. Google Scholar 6. Boston Scientific Corporation: Intended use. In: Rezum Instruction for Use, 10-2019 p. 5. Google Scholar 7. : Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezum(R) system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol 2015; 7: 13. Google Scholar 8. : Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia. BMC Urol 2006; 6: 14. Google Scholar 9. : Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia?J Sex Med 2018; 15: 1728. Google Scholar 10. National Institute for Health and Care Excellence: Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (24 June 2020). NICE Guideline No. MTG49. Available at https://www.nice.org.uk/guidance/mtg49. Google Scholar 11. : EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Arnhem, The Netherlands: EAU Guidelines Office 2020. Available at http://uroweb.org/guidelines/compilations-of-all-guidelines/. Google Scholar 12. : Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology 2019; 126: 171. Google Scholar 13. : Three-year outcomes of the prospective, randomized controlled Rezum System Study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology 2018; 111: 1. Google Scholar 14. : Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol 2017; 197: 1507. Link, Google Scholar 15. : Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2016; 195: 1529. Link, Google Scholar 16. : Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J Urol 2014; 191: 1828. Link, Google Scholar 17. : Prostatic urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift study. Prostate Cancer Prostatic Dis 2019; 22: 411. Google Scholar 18. U.S. Food and Drug Administration: Select Updates for Guidance for the Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH): Draft Guidance for Industry and Food and Drug Administration Staff (July 14, 2020). Available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/select-updates-guidance-non-clinical-and-clinical-investigation-devices-used-treatment-benign. Google Scholar 19. : Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial. J Urol 2012; 187: 1732. Link, Google Scholar 20. : Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 2017; 24: 8802. Google Scholar 21. : Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003; 44: 89. Google Scholar 22. : Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails. J Urol 2007; 177: 1047. Link, Google Scholar 23. : Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol 2004; 171: 2336. Link, Google Scholar 24. : Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. J Urol 200; 405: 2018. Google Scholar 25. : Costs of managing benign prostatic hyperplasia in the office and operating room. Curr Urol Rep 2018; 19: 72. Google Scholar 26. : Surgical reintervention rate after prostatic urethral lift: systematic review and meta-analysis involving over 2,000 patients. J Urol 2020; 204: 1019. Link, Google Scholar 27. : Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol 2006; 50: 969. Google Scholar 28. : Long-term clinical efficacy and safety profile of transurethral resection of prostate versus plasmakinetic resection of the prostate for benign prostatic hyperplasia. Urology 2017; 103: 198. Google Scholar 29. : Potassium-titanyl-phosphate laser photoselective vaporization for benign prostatic hyperplasia: 5-year follow-up from a district general hospital. J Endourol 2012; 26: 878. Google Scholar 30. : Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. J Urol 2011; 185: 1804. Link, Google Scholar Funding for this study was provided by Boston Scientific. © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsRelated articlesJournal of UrologyJun 2, 2021, 12:00:00 AMEditorial CommentJournal of UrologyJun 2, 2021, 12:00:00 AMEditorial Comment Volume 206Issue 3September 2021Page: 715-724Supplementary Materials Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.Keywordsurologic surgical procedures, maleprostateminimally invasive surgical proceduresprostatic hyperplasiaAcknowledgmentsWe would like to acknowledge the contributions of Kyle DeRouen, Sirikan Rojanasarot, PhD, Amit Mondal, MS, Kevin Hagelin, and the Boston Scientific Clinical Operations and Biostatistics Teams.MetricsAuthor Information Kevin T. McVary Loyola University Medical Center, Maywood, Illinois *Correspondence: Center for Male Health, Stritch School of Medicine, Loyola University Medical Center, 2160 S. First Ave., Maywood, Illinois 60153 telephone: 708-216-3166; FAX: 708-216-6585; E-mail Address: [email protected] Financial interest and/or other relationship with Boston Scientific, NIDDK, Astellas, Olympus, SRS Medical Systems, Medeonbio, Uronext LL. Patent holder: SMA penile prosthesis (US20130131443), magnetic induction SMA (US506777291). More articles by this author Marc C. Gittelman South Florida Medical Research, Aventura, Florida Financial interest and/or other relationship with NxThera. More articles by this author Kenneth A. Goldberg University of Texas Southwestern, Lewisville, Texas More articles by this author Kalpesh Patel Arizona Institute of Urology, Tucson, Arizona More articles by this author Neal D. Shore Carolina Urologic Research Center, Myrtle Beach, South Carolina Financial interest and/or other relationship with NxThera. Financial interest and/or other relationship with Boston Scientific, TELEFLEX, Zenflow, Medeon, GSK. More articles by this author Richard M. Levin Chesapeake Urology Research Associates, Towson, Maryland Financial interest and/or other relationship with Boston Scientific, TELEFLEX, Zenflow, Medeon, GSK. More articles by this author Marc Pliskin The Urology Group, Cincinnati, Ohio More articles by this author J. Randolf Beahrs Minnesota Urology, Woodbury, Minnesota More articles by this author David Prall Minnesota Urology, Woodbury, Minnesota More articles by this author Jed Kaminetsky Manhattan Medical Research, New York, New York More articles by this author Barrett E. Cowan Urology Associates of Denver, Englewood, Colorado Financial interest and/or other relationship with Procept Biorobotics. More articles by this author Christopher H. Cantrill Urology San Antonio Research, San Antonio, Texas Financial interest and/or other relationship with Boston Scientific, TELEFLEX, Zenflow, Medeon, GSK. More articles by this author Lance A. Mynderse Mayo Clinic, Rochester, Minnesota More articles by this author James C. Ulchaker Cleveland Clinic, Cleveland, Ohio Financial interest and/or other relationship with Boston Scientific, TELEFLEX, Zenflow, Medeon, GSK. More articles by this author Nicholas N. Tadros Southern Illinois University, Springfield, Illinois Financial interest and/or other relationship with NxThera. Financial interest and/or other relationship with Boston Scientific, TELEFLEX, Zenflow, Medeon, GSK. More articles by this author Steven N. Gange Western Urologic Clinic, Salt Lake City, Utah Financial interest and/or other relationship with NeoTract. More articles by this author Claus G. Roehrborn University of Texas Southwestern, Dallas, Texas Financial interest and/or other relationship with Boston Scientific, TELEFLEX, Zenflow, Medeon, GSK. More articles by this author Expand All Funding for this study was provided by Boston Scientific. Advertisement PDF DownloadLoading ...